ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,167.37
-0.38%
Dow Jones
40,464.83
0.12%
Gold vs US Dollar
2,404.35
0.35%
Brent Oil
80.25
-1.55%
Bitcoin
65,859.27
-2.58%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) News

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SUPN
DateTimeSourceHeadlineSymbolCompany
22/07/202421:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/07/202421:28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/07/202421:18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/07/202421:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/07/202421:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/07/202421:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
15/07/202421:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
17/06/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SUPNSupernus Pharmaceuticals Inc
17/06/202421:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
30/05/202421:25GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
23/05/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
23/05/202421:05GlobeNewswire Inc.Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in EpilepsyNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/05/202421:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
09/05/202421:05GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant SeizuresNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
08/05/202421:05GlobeNewswire Inc.Supernus Announces First Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
07/05/202415:00PR Newswire (US)M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin AmericaNASDAQ:SUPNSupernus Pharmaceuticals Inc
01/05/202413:00GlobeNewswire Inc.Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree StoryNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/04/202421:05GlobeNewswire Inc.Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
08/04/202413:00GlobeNewswire Inc.Supernus Provides Regulatory Update for SPN-830NASDAQ:SUPNSupernus Pharmaceuticals Inc
06/03/202421:30GlobeNewswire Inc.Supernus to Participate in Two Upcoming Investor ConferencesNASDAQ:SUPNSupernus Pharmaceuticals Inc
29/02/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
29/02/202422:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/02/202421:30GlobeNewswire Inc.Supernus to Participate in the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202422:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202422:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SUPN

Your Recent History

LSE
GDR
Genedrive
LSE
ZPHR
Zephyr Energy
LSE
LLOY
Lloyds Banking
LSE
TERN
Tern
LSE
QBT
Quantum Blockchain Techn...
LSE
THG
Thg
LSE
HUM
Hummingbird Resources
LSE
PANR
Pantheon Resources
LSE
YU.
Yu
LSE
ZED
Zenova
LSE
SOLG
Solgold
LSE
SBTX
Skinbiotherapeutics
LSE
OPTI
Optibiotix Health
LSE
HVO
Hvivo
LSE
UPS
LSE
PHNX
Phoenix
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved